Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

841.00INR
21 Nov 2014
Price Change (% chg)

Rs-10.05 (-1.18%)
Prev Close
Rs851.05
Open
Rs846.25
Day's High
Rs857.00
Day's Low
Rs839.00
Volume
1,813,772
Avg. Vol
2,573,503
52-wk High
Rs932.50
52-wk Low
Rs552.55

SUN.NS

Chart for SUN.NS

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.60
Market Cap (Mil.): Rs1,762,664.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.18

Financials

  SUN.NS Industry Sector
P/E (TTM): 30.34 38.05 39.20
EPS (TTM): 28.05 -- --
ROI: -- 17.86 17.16
ROE: -- 18.61 18.09
Search Stocks

Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

MUMBAI - Sun Pharmaceutical Industries, India's largest drugmaker by revenue, on Thursday posted a 15 percent rise in quarterly net profit, roughly in line with expectations, helped by strong growth in sales in the domestic market.

13 Nov 2014

Ranbaxy books first profit in six quarters on exclusive drug launch

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd on Tuesday reported its first profit in six quarters after benefiting from the exclusive U.S. launch of a cheaper copy of Novartis AG blood pressure pill Diovan.

28 Oct 2014

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

28 Oct 2014

Ranbaxy surges after profit, Sun Pharma also gains

Reuters Market Eye - Ranbaxy Laboratories gains 4.5 percent. Sun Pharmaceutical Industries , which is in the process of acquiring Ranbaxy, also jumps 4.4 percent.

28 Oct 2014

MARKET EYE -India's Ranbaxy surges after profit, Sun Pharma also gains

* Ranbaxy Laboratories gains 4.5 percent. * Sun Pharmaceutical Industries, which is in the process of acquiring Ranbaxy, also jumps 4.4 percent. * Ranbaxy posts a profit of 4.78 billion rupees ($78 million), compared with a loss of 4.5 billion rupees a year earlier. * The company's earnings got a boost from the launch of generic Valsartan in the U.S. with 180 days exclusivity - Analysts. * Valsartan is a cheaper copy of Novartis AG's blood pressure pill Diovan. * The Indian pharma index gaine

28 Oct 2014

Sun Pharma gains on cash position, receding USFDA risk

Reuters Market Eye - Sun Pharmaceutical Industries gains 3.3 percent.

29 Sep 2014

MARKET EYE -India's Sun Pharma gains on cash position, receding USFDA risk

* Sun Pharmaceutical Industries gains 3.3 percent. * Adds to Friday's 4.2 percent surge. * Strong cash position, receding U.S. FDA risk seen as main reasons for gains. * Company had cash and cash equivalents of 75.90 billion rupees as on March 31, 2014, annual report shows. * Gains also helped as rupee weakens, which would help boost returns from overseas markets. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

29 Sep 2014

Sun Pharma head towards biggest daily gain in 5-1/2 months

Reuters Market Eye - Sun Pharmaceutical Industries gains more than 6 percent.

26 Sep 2014

MARKET EYE -India's Sun Pharma gains; becomes first to license drug from innovator

* Sun Pharmaceutical Industries gains 2 percent. * Merck & Co Inc said it had licensed its experimental psoriasis drug to Sun. * First instance of an Indian company taking global rights for a novel drug, traders say. * Deal strengthens Sun's presence in the U.S. skin market, also boosts revenue potential, traders add. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

18 Sep 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

Earnings vs. Estimates

Search Stocks